Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system

被引:25
作者
Ogiwara, K. [1 ]
Nogami, K. [1 ]
Hosokawa, K. [2 ]
Ohnishi, T. [2 ]
Matsumoto, T. [1 ]
Shima, M. [1 ]
机构
[1] Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan
[2] Fujimori Kogyo Co, Res Inst, Yokohama, Kanagawa, Japan
关键词
clinical phenotype; desmopressin; factor VIII; flow chamber system; von Willebrand disease; von Willebrand factor; FACTOR-VIII BINDING; THROMBUS FORMATION; DIAGNOSIS; PATHOPHYSIOLOGY; MULTIMERIZATION; DOMAIN; BLOOD;
D O I
10.1111/hae.12610
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The diagnosis of von Willebrand disease (VWD) is difficult due to the wide spectrum of clinical phenotypes associated with this disorder. We have analysed and characterized haemostatic function in VWD patients using a microchip-based flow chamber system. Microchips coated with either collagen [platelet (PL)-chip] or collagen/thromboplastin [atherome (AR)-chip] were used to evaluate platelet thrombus formation at 1000 s(-1) and fibrin-rich platelet thrombus formation at 240 s(-1) respectively. Blood samples from an asymptomatic patient with VWD type 1 [von Willebrand factor (VWF): RCo 3.2%; bleeding score (BS 2] displayed normal thrombus formation in both PL- and AR-chips, whereas blood from a symptomatic type 1 patient (VWF: RCo 14%, BS 9) had significantly delayed capillary occlusion. Nearly complete suppression of the flow pressure increase was observed in symptomatic patients with VWD type 2A (BS 13) and 2N (BS 27), whereas no flow pressure was found for the type 3 patient (BS 6). Fibrin-rich platelet thrombus formation was only weakly increased by the in vitro addition of factor VIII (FVIII) to blood samples from the type 3 patient, but was normalized by the addition of VWF/FVIII. The in vivo effects of treatment with desmopressin or VWF/FVIII for the symptomatic patients were analysed using two types of microchips. The PL-chip was highly sensitive for patients' VWF-mediated platelet functions, whereas the AR-chip allowed assessment of overall haemostatic ability, including sensitivity to both VWF and FVIII. The combined analysis with PL- and AR-chips may be potentially useful for the diagnosis of VWD based on clinical phenotypes, and for monitoring drug effects.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 23 条
[1]   Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor [J].
Allen, S ;
Abuzenadah, AM ;
Blagg, JL ;
Hinks, J ;
Nesbitt, IM ;
Goodeve, AC ;
Gursel, T ;
Ingerslev, J ;
Peake, IR ;
Daly, ME .
BLOOD, 2000, 95 (06) :2000-2007
[2]   Principles of care for the diagnosis and treatment of von Willebrand disease [J].
Castaman, Giancarlo ;
Goodeve, Anne ;
Eikenboom, Jeroen .
HAEMATOLOGICA, 2013, 98 (05) :667-674
[3]   The impact of bleeding history, von Willebrand factor and PFA-100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD [J].
Castaman, Giancarlo ;
Tosetto, Alberto ;
Goodeve, Anne ;
Federici, Augusto B. ;
Lethagen, Stefan ;
Budde, Ulrich ;
Batlle, Javier ;
Meyer, Dominique ;
Mazurier, Claudine ;
Goudemand, Jenny ;
Eikenboom, Jeroen ;
Schneppenheim, Reinhard ;
Ingerslev, Jorgen ;
Habart, David ;
Hill, Frank ;
Peake, Ian ;
Rodeghiero, Francesco .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (03) :245-251
[4]   A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions [J].
Hosokawa, K. ;
Ohnishi, T. ;
Kondo, T. ;
Fukasawa, M. ;
Koide, T. ;
Maruyama, I. ;
Tanaka, K. A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (10) :2029-2037
[5]   Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions [J].
Hosokawa, Kazuya ;
Ohnishi, Tomoko ;
Sameshima, Hisayo ;
Miura, Naoki ;
Ito, Takashi ;
Koide, Takehiko ;
Maruyama, Ikuro .
THROMBOSIS AND HAEMOSTASIS, 2013, 109 (01) :102-111
[6]   A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization [J].
Jorieux, S ;
Gaucher, C ;
Goudemand, J ;
Mazurier, C .
BLOOD, 1998, 92 (12) :4663-4670
[7]  
KUNDU SK, 1995, SEMIN THROMB HEMOST, V21, P106
[8]   Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology [J].
Mazurier, C ;
Goudemand, J ;
Hilbert, L ;
Caron, C ;
Fressinaud, E ;
Meyer, D .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) :337-347
[9]  
Nishino M, 1996, INT J HEMATOL, V64, P127
[10]   Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood [J].
Ogawa, S. ;
Szlam, F. ;
Dunn, A. L. ;
Bolliger, D. ;
Ohnishi, T. ;
Hosokawa, K. ;
Tanaka, K. A. .
HAEMOPHILIA, 2012, 18 (06) :926-932